Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $235.5M
Founded date: 2018
Founders name: Chris Varma
Founders Related Locations: United States, California, San Francisco
Investors 5
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | DCVC | dcvc.com/ |
| - | RA Capital... | racap.com |
| - | Droia Onco... | droiaventu... |
| - | Berkeley C... | berkeleyca... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.02.2024 | Series C | $80M | - |
| 20.07.2021 | Series B | $88.5M | - |
| 25.06.2019 | Series A | $67M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Chris | Varma | Co-Founder... | linkedin.c... | - | - |
Mentions in press and media 20
| Date | Title | Description | Source |
| 06.03.2024 | Frontier Medicines to Present Preclinical Data at the Americ... | - | globenewsw... |
| 26.02.2024 | Retail investors have been clamoring to invest in AI. With F... | The old saying goes something like this: If you can’t get in the front door, go through the back, an... | fortune.co... |
| 25.02.2024 | Frontier Medicines Receives $80M in Series C Financing | Frontier Medicines Corporation, a Boston, MA- and San Francisco, CA-based precision medicine company... | finsmes.co... |
| 23.02.2024 | Frontier Medicines Secures $80 Million for Clinical-Stage Pi... | Frontier Medicines, a precision medicine company, has successfully closed an oversubscribed $80 mill... | parsers.vc... |
| 23.02.2024 | Frontier Medicines Inks $80M Series C | BOSTON, MA, Frontier Medicines today announced the close of an oversubscribed $80 million Series C... | vcnewsdail... |
| 22.02.2024 | Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024... | Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclu... | einpresswi... |
| 22.02.2024 | Galapagos announces full year 2023 results and outlook for 2... | Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales o... | einpresswi... |
| 22.02.2024 | Frontier Medicines Announces Oversubscribed $80 Million Seri... | - | globenewsw... |
| 22.02.2024 | Frontier Medicines Announces Oversubscribed $80 Million Seri... | - First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a f... | einpresswi... |
| 20.07.2021 | Frontier Medicines raises $88M for R&D, including potent... | Amgen received FDA approval earlier this year for a drug that targets a rare mutation once deemed “u... | medcitynew... |
Show more